Indirect bronchial hyperresponsiveness in asthma: Mechanisms, pharmacology and implications for clinical research

European Respiratory Journal

Volumn 16, Issue 3, 2000, Pages 514-533

  Van Schoor, J ^a   Joos, G F ^a   Pauwels, R A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adenosine challenge; Airway inflammation; Asthma; Bronchial challenges; Bronchial hyperresponsiveness; Exercise challenge

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ADENOSINE PHOSPHATE; ASTEMIZOLE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BUDESONIDE; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; FLUTICASONE PROPIONATE; FUROSEMIDE; HEPARIN; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; NEDOCROMIL SODIUM; PROPRANOLOL; PROSTAGLANDIN D2; SODIUM METABISULFITE; SULFUR DIOXIDE; TACHYKININ; TACHYKININ RECEPTOR ANTAGONIST; UNINDEXED DRUG;

AEROSOL; AIRWAY; ASTHMA; BRONCHUS HYPERREACTIVITY; EXERCISE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ADRENERGIC BETA-ANTAGONISTS; AEROSOLS; ASTHMA; BRADYKININ; BRONCHIAL HYPERREACTIVITY; BRONCHOCONSTRICTOR AGENTS; EXERCISE; HUMAN; PROPRANOLOL; PULMONARY VENTILATION; SULFITES; SULFUR DIOXIDE; TACHYKININS;

EID: 0033797030     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.016003514.x     Document Type: Review

References (296)

1. Bronchial hyperresponsiveness
2. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma
3. Airway hyperresponsiveness - Relation to asthma and inflammation
4. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal. Official position of the European Respiratory Society
5. Guidelines for methacholine and exercise challenge testing-1999
6. Adenosine
7. Adenosine (P1) receptor signalling
8. Adenosine receptors involved in the bronchoconstrictor effect of adenosine
9. Adenosine A2B receptors: A novel therapeutic target in asthma?
10. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects
11. The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5'-monophosphate, and allergen in atopic nonasthmatic subjects
12. The effect of inhaled adenosine 5'-monophosphate (AMP) on airway calibre in normal and asthmatic subjects
13. Airway refractoriness to adenosine 5'-monophosphate after repeated inhalation
14. Airway responsiveness to adenosine 5' monophosphate following inhalation of hypertonic saline
15. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism
16. Adenosine Potentiates mediator release from human lung mast cells
17. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma
18. Bronchial challenge with adenosine causes the release of serum neutrophil chemotactic factor in asthma
19. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine
20. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma
21. Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5'-monophosphate in non-atopic asthma
22. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects
23. Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects
24. Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'- monophosphate challenge in asthma
25. Effect of indomethacin on adenosine-induced bronchoconstriction
26. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma
27. The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 5'-monophosphate and histamine in asthma
28. Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma
29. Neutral endopeptidase inhibition with inhaled phosphoramidon: No effect on bronchial responsiveness to adenosine 5'-monophosphate (AMP) in asthma
30. A comparison of the inhibitory effects of nedocromil sodium and SCG on adenosine monophosphate-induced bronchoconstriction in atopic subjects
31. Comparative study of the effects of nedocromil sodium (4 mg) and SCG (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects
32. Nedocromil sodium is more potent than SCG against AMP-induced bronchoconstriction in atopic asthmatic subjects
33. Chloride transport and the action of SCG and nedocromil sodium in asthma
34. Effect of endogenous nitric oxide inhibition on airway responsiveness to histamine and adenosine-5'-monophosphate in asthma
35. Inhibition of adenosine 5'-monophosphate- and methacholine-induced bronchoconstriction in asthma by inhaled frusemide
36. Effect of inhaled frusemide on responses of airways to bradykinin and adenosine 5'-monophosphate in asthma
37. Time course of changes in adenosine 5'-monophosphate airway responsiveness with inhaled heparin in allergic asthma
38. Effect of inhaled heparin on adenosine-induced bronchial hyperreactivity
39. Greater effect of inhaled budesonide on adenosine 5'-monophosphate- induced than on sodium-metabisulfite-induced bronchoconstriction in asthma
40. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5' monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze
41. Airway hyperresponsiveness: Relation to asthma and inflammation?
42. Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5'-monophosphate, and exercise in asthmatic children
43. Adenosine bronchoprovocation: A promising marker of allergic inflammation in asthma?
44. Sensory neuropeptides and the human lower airways: Present state and future directions
45. Sensory peptides and airway diseases
46. The effects of tachykinins on inflammatory and immune cells
47. Human monocytes and macrophages express substance P and neurokinin-1 receptor
48. Tachykinin receptors and airway pathophysiology
49. Characterization of neurokinin effects and receptor selectivity in human isolated bronchi
50. Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors
51. Pharmacological examination of receptors mediating contractile responses to tachykinins in airways isolated from human, guinea pig and hamster
52. Evidence for functional tachykinin NK1 receptors on human isolated small bronchi
53. Regulation of airway neurogenic inflammation by neutral endopeptidase
54. Peptidase modulation of neurogenic inflammation
55. Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects
56. Effect of nedocromil on bronchospasm induced by inhalation of substance P in asthmatic subjects
57. The effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responses to neurokinin A in normal humans in vivo
58. Neutral endopeptidase activity and airway hyperresponsiveness to neurokinin A in asthmatic subjects in vivo
59. Substance P-induced cutaneous and bronchial reactions in children with bronchial asthma
60. Inhibition of neutral endopeptidase potentiates bronchoconstriction induced by neurokinin A in asthmatic patients
61. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics
62. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics
63. Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P.
64. The effect of oral terfenadine on neurokinin-A-induced bronchoconstriction
65. Comparison of the histamine-releasing action of substance P on mast cells and basophils from different species and tissues
66. Substance P induces histamine release from human pulmonary mast cells
67. Changes in neurokinin A airway responsiveness with inhaled lysine-acetylsalicylate in asthma
68. The effect of oxitropium bromide on neurokinin A-induced bronchoconstriction in asthmatic subjects
69. The effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in subjects with asthma
70. Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma
71. The effects of inhaled fluticasone propionate on methacholine- and neurokinin A-induced bronchoconstriction in asthmatics
72. Kinins as mediators of lung disease
73. The effect of bradykinin aerosol in guinea-pigs and in man
74. The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children
75. In vivo and in vitro effect of bradykinin on bronchial motor tone in normal subjects and patients with airways obstruction
76. Bradykinin-induced bronchoconstriction in humans. Mode of action
77. Comparative airway response to inhaled bradykinin, kallidin, and [des- Arg9]bradykinin in normal and asthmatic subjects
78. Dissociation of bradykinin-induced plasma exudation and reactivity in the peripheral airways
79. Contractile effects of bradykinin on the isolated human small bronchus
80. Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin B-2 and thromboxane prostanoid receptors
81. Effect of an inhaled neutral endopeptidase inhibitor, phosphoramidon, on baseline airway calibre and bronchial responsiveness to bradykinin in asthma
82. Cross-tachyphylactic airway response to inhaled bradykinin, kallidin and [desArg9]-bradykinin in asthmatic subjects
83. Tachyphylaxis of airway response to inhaled bradykinin over several days
84. Factors determining bradykinin bronchial responsiveness and refractoriness in asthma
85. Cross refractoriness between bradykinin and hypertonic saline challenges in asthma
86. Contribution of histamine and prostanoids to bronchoconstriction provoked by inhaled bradykinin in atopic asthma
87. 2 induction
88. Activity of inhaled lysine acetylsalicylate (L-ASA) on bradykinin- induced bronchoconstriction in asthmatics: Evidence of contribution of prostaglandins
89. The influence of cyclooxygenase inhibition on the loss of bronchoconstrictor response to repeated bradykinin challenge in asthma
90. Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction
91. Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma
92. Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications
93. Bradykinin-induced bronchoconstriction in guinea pig in vivo: Role of neural mechanisms
94. Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation
95. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist
96. Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-224 in asthmatic subjects
97. Bradykinin-induced bronchoconstriction: Inhibition by nedocromil sodium and SCG
98. The action of SCG on 'C' fibre endings in the dog lung
99. Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma
100. Furosemide inhibits bradykinin-induced contraction of human bronchi: Role of thromboxane A2 receptor antagonism
101. Action of budesonide on asthmatic bronchial hyperresponsiveness. Effects on directly and indirectly acting bronchoconstrictors
102. Sulfite sensitivity
103. The roles of pH and ionic species in sulfur dioxide- and sulfite-induced bronchoconstriction
104. Mechanism of bronchoconstriction during inhalation of sulfur dioxide
105. Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide
106. Bronchospastic responses to aerosolized metabisulfite in asthmatic subjects: Potential mechanisms and clinical implications
107. Role of bronchial irritant receptors in asthma
108. Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite
109. 2 on respiratory mechanisms in healthy male adults
110. Refractoriness to inhaled sodium metabisulphite in subjects with mild asthma
111. Tolerance to sulfur dioxide-induced bronchoconstriction in subjects with asthma
112. Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction
113. Cross refractoriness between sodium metabisulphite and exercise induced asthma
114. Metabisulphite induced bronchoconstriction: Mechanisms
115. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma
116. Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromide
117. Characterisation of bronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects with and without asthma
118. Neutral endopeptidase inhibitor thiorphan increases airway narrowing to inhaled sodium metabisulfite in normal subjects
119. Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects
120. 2) in sodium metabisulfite-induced airway effects
121. Inhaled sodium metabisulphite induced bronchoconstriction: Inhibition by nedocromil sodium and SCG
122. The effect of the nitric oxide synthase inhibitor, L-NMMA, on sodium metabisulphite-induced bronchoconstriction and refractoriness in asthma
123. Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects
124. A comparison of the effects of inhaled furosemide and ethacrynic acid on sodium-metabisulfite-induced bronchoconstriction in subjects with asthma
125. Inhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma: Role of cyclooxygenase products
126. Effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma
127. The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma
128. Effect of inhaled magnesium sulfate on sodium metabisulfite-induced bronchoconstriction in asthma
129. Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma
130. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma
131. A new method of inhalation challenge with propranolol: Comparison with methacholine-induced bronchoconstriction and role of vagal nerve activity
132. Propranolol inhalation challenge in relation to histamine response in children with asthma
133. Bronchial responsiveness to inhaled propranolol in asthmatic children and adults
134. Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics
135. 1 and on propranolol airways responsiveness in atopic subjects with asthma
136. Provocative dose and dose-response curve to inhaled propranolol in asthmatic patients with bronchial hyperresponsiveness to methacholine
137. Propranolol-induced bronchoconstriction in asthma: Beta-receptor blockade and mediator release
138. Plasma histamine concentration during propranolol induced bronchoconstriction
139. Effect of oral terfenadine on the bronchoconstrictor response to inhaled propranolol and histamine in asthmatics
140. Effect of leukotriene and thromboxane antagonist on propranolol-induced bronchoconstriction
141. Anticholinergic blockade of beta-blocker-induced bronchoconstriction
142. Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol
143. Beta-blocker induced asthma: A role for sensory nerve hyperresponsiveness?
144. Protective effect of diSCG on propranolol challenge
145. Effect of inhaled diSCG and nedocromil sodium on propranolol-induced bronchoconstriction
146. Attenuation of propranolol-induced bronchoconstriction by frusemide
147. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between budesonide and terbutaline
148. Exercise-induced asthma
149. Is there a unifying hypothesis for exercise-induced asthma?
150. Hypothesis: Exercise-induced asthma as a vascular phenomenon
151. A comparison of the osmotic activation of basophils and human lung mast cells
152. The refractory period after exercise-induced asthma: Its duration and relation to the severity of exercise
153. A comparison of the refractory periods induced by hypertonic airway challenge and exercise in bronchial asthma
154. Repeated exposure of asthmatic airways to inhaled adenosine 5'-monophosphate attenuates bronchoconstriction provoked by exercise
155. Terfenadine in exercise induced asthma
156. Effect of terfenadine on the response to exercise and cold air in asthma
157. Terfenadine blockade of exercise-induced bronchospasm
158. Evidence for the roles of histamine and prostaglandins as mediators in exercise-induced asthma: The inhibitory effect of terfenadine and flurbiprofen alone and in combination
159. The effect of indomethacin on exercise-induced bronchoconstriction and refractoriness after exercise
160. Indomethacin blocks airway tolerance to repetitive exercise but not to eucapnic hyperponea in asthmatic subjects
161. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma
162. 2 on exercise-induced bronchoconstriction in asthmatic subjects
163. Effects of prostacyclin on aspecifically and specifically induced bronchoconstriction in asthmatic patients
164. Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma
165. Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction
166. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist
167. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor
168. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients
169. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist
170. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK and F 104353). A double-blind study versus diSCG and placebo
171. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
172. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
173. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges
174. A comparison of ketotifen with clemastine, ipratropium bromide and SCG in exercise-induced asthma
175. Effect of lignocaine, SCG, and ipratropium bromide in exercise-induced asthma
176. SCG and ipratropium bromide in exercise-induced asthma
177. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients
178. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults
179. Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise-induced asthma
180. Cromolyn versus nedocromil: Duration of action in exercise-induced asthma in children
181. Dose-response effect of SCG pressurised aerosol in exercise induced asthma
182. Dose-response study of nebulised nedocromil sodium in exercise induced asthma
183. Prevention of exercise-induced bronchoconstriction by inhaled frusemide
184. Inhaled frusemide and exercise induced asthma: Evidence of a role for inhibitory prostanoids
185. Hyperventilation-induced asthma: Evidence for two mechanisms
186. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin
187. Effect of inhalation of corticosteroids on exercise induced asthma: Randomised double blind cross-over study of budesonide in asthmatic children
188. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. Dutch CNSLD Study Group
189. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma
190. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline
191. Evaluation of ultrasonically nebulised solutions for provocation testing in patients with asthma
192. Hyperosmolarity as the stimulus to asthma induced by hyperventilation?
193. Inhalation of hypertonic saline as a bronchial challenge in children with mild asthma and normal children
194. Hypertonic saline challenge in an epidemiologic survey of asthma in children
195. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone
196. The effect of inhaling a dry powder of sodium chloride on the airways of asthmatic subjects
197. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol
198. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma
199. Indomethacin and airway responsiveness to repeated 4.5% NaCl challenges
200. Changes in sensitivity to methacholine after inhalation with distilled water: The role of the bronchoconstrictive response
201. Airway responses to hypertonic saline, exercise and histamine challenges in bronchial asthma
202. Inhalational challenge using hypertonic saline in asthmatic subjects: A comparison with responses to hyperpnoea, methacholine and water
203. Methacholine responsiveness increases after ultrasonically nebulized water but not after ultrasonically nebulized hypertonic saline in patients with asthma
204. Comparison of bronchial challenge with ultrasonic nebulized distilled water and hypertonic saline in children with mild-to-moderate asthma
205. Effects of hyperosmolarity on human isolated central airways
206. Mediator release in an isolated airway segment in subjects with asthma
207. Airway effects of local challenge with hypertonic saline in exercise-induced asthma
208. Role of histamine release in hypertonic saline induced bronchoconstriction
209. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine
210. Terfenadine modifies airway narrowing induced by the inhalation of nonisotonic aerosols in subjects with asthma
211. Inhaled clemastine, an HI antihistamine inhibits airway narrowing caused by aerosols of non-isotonic saline
212. The effects of indomethacin on the refractory period to hypertonic saline-induced bronchoconstriction
213. The contribution of neurogenic reflexes to hypertonic saline-induced bronchoconstriction in asthma
214. Vagal afferent and reflex responses to changes in surface osmolarity in lower airways of dogs
215. Sensory neuropeptides and airway function
216. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects
217. Acute effect of SCG on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma
218. Nedocromil sodium inhibits the airway response to hyperosmolar challenge in patients with asthma
219. The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: A role for the airway epithelium?
220. The effect of inhaled frusemide on airway sensitivity to inhaled 4.5% sodium chloride aerosol in asthmatic subjects
221. Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects
222. Inhaled steroids modify bronchial responses to hyperosmolar saline
223. Airway responsiveness in asthma: Bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide
224. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal
225. Exercise-induced asthma and the use of hypertonic saline aerosol as a bronchial challenge
226. Reactivity of the bronchial tree to different stimuli
227. Mist therapy reconsidered; an evaluation of the respiratory deposition of labelled water aerosols produced by jet and ultrasonic nebulizers
228. Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water
229. Incorporation and analysis of ultrasonically nebulized distilled water challenges in an epidemiologic study of asthma and bronchial reactivity
230. Refractory period to ultrasonic mist of distilled water: Relationship to methacholine responsiveness, atopic status, and clinical characteristics
231. The effect of indomethacin on the refractory period occurring after the inhalation of ultrasonically nebulized distilled water
232. Increase in bronchial responsiveness to methacholine and late asthmatic response after the inhalation of ultrasonically nebulized distilled water
233. Increased responsiveness to methacholine and histamine after challenge with ultrasonically nebulised water in asthmatic subjects
234. Cromolyn sodium inhibits the increased responsiveness to methacholine that follows ultrasonically nebulized water challenge in patients with asthma
235. Bronchoconstriction induced by distilled water. Sensitivity in asthmatics and relationship to exercise-induced bronchospasm
236. Comparison of bronchial reactivity to ultrasonically nebulized distilled water, exercise and methacholine challenge test in asthmatic children
237. Comparison of bronchial responses to ultrasonically nebulized distilled water, exercise, and methacholine in asthma
238. Comparison of ultrasonically nebulized distilled water and hyperventilation with cold air in asthma
239. Comparison of cold air, ultrasonic mist, and methacholine inhalations as tests of bronchial reactivity in normal and asthmatic children
240. Comparison of ultrasonically nebulized distilled water and cold-air hyperventilation challenges in asthmatic patients
241. Distilled water challenges in asthmatic children. Comparison of different protocols
242. Effect of hypo- and hyperosmolarity on basophil histamine release
243. Effect of terfenadine on the bronchoconstriction induced by ultrasonically nebulized distilled water
244. Control of the bronchial tone
245. Protective activity of inhaled nonsteroidal antiinflammatory drugs on bronchial responsiveness to ultrasonically nebulized water
246. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids
247. Effect of ipratropium bromide and/or SCG pretreatment on water-induced bronchoconstriction in asthma
248. The protective effects of ipratropium bromide and terbutaline on distilled water-induced bronchoconstriction
249. Drug effect on bronchial response to PGF2 alpha and water inhalation
250. Mechanism of cough and bronchoconstriction induced by distilled water aerosol
251. Effect of atropine on the bronchial response of asthmatic subjects to the inhalation of ultrasonically nebulized distilled water
252. Morphine sulfate inhibits bronchoconstriction in subjects with mild asthma whose responses are inhibited by atropine
253. Role of tachykinins in distilled water-induced bronchoconstriction in guinea-pigs
254. Inhibition of fog-induced bronchoconstriction by nedocromil sodium and SCG in intrinsic asthma: A double-blind, placebo-controlled study
255. Effect of inhaled furosemide and cromolyn on bronchoconstriction induced by ultrasonically nebulized distilled water in asthmatic subjects
256. Prevention of fog-induced bronchospasm by nedocromil sodium
257. Effect of nedocromil sodium on bronchial hyperreactivity in children with nonatopic asthma
258. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water
259. Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction
260. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma
261. Hyperventilation asthma
262. The refractory period after eucapnic voluntary hyperventilation challenge and its effect on challenge technique
263. The role of hyperventilation in exercise-induced bronchoconstriction
264. The time course of bronchoconstriction in asthmatics during and after isocapnic hyperventilation
265. Respiratory heat loss is not the sole stimulus for bronchoconstriction induced by isocapnic hyperponea with dry air
266. A comparison between the airway response to isocapnic hyperventilation and hypertonic saline in subjects with asthma
267. Isocapnic hyperventilation with cold air in healthy non-smokers, smokers and asthmatic subjects
268. Airway effects of respiratory heat loss in normal subjects
269. The bronchial response to cold air challenge: Evidence for different mechanisms in normal and asthmatic subjects
270. Response to cold air hyperventilation in normal and in asthmatic children
271. Hyperventilation-induced asthma: Evidence for two mechanisms
272. Refractory period after hyperventilation-induced asthma
273. Analysis of refractory period after exercise and eucapnic voluntary hyperventilation challenge
274. Attenuation of hyperventilation-induced bronchospasm by terfenadine: A new antihistamine
275. The relative contributions of histamine and prostanoids to bronchoconstriction provoked by isocapnic hyperventilation in asthma
276. Hyperventilation stimulates the release of prostaglandin I2 and E2 from lung in humans
277. Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma
278. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air
279. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects
280. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air
281. Dose-dependent inhibition of cold-air-induced bronchoconstriction by atropine
282. Bronchial responsiveness to hyperventilation in children with asthma: Inhibition with ipratropium bromide
283. Interaction of cromolyn and a muscarinic antagonist in inhibiting bronchial reactivity to sulfur dioxide and to eucapnic hyperponea alone
284. Tachykinin receptor antagonists inhibit hyperpnea-induced bronchoconstriction in guinea-pigs
285. Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone
286. Protective effect of nedocromil sodium and SCG on bronchospasm induced by cold air
287. Airway constriction by isocapnic hyperventilation of cold, dry air: Comparison of magnitude and duration of protection by nedocromil sodium and SCG
288. Effect of inhaled furosemide on the bronchial response to methacholine and cold-air hyperventilation challenges
289. Different effects of inhaled amiloride and frusemide on airway responsiveness to dry air challenge in asthmatic subjects
290. Inhaled frusemide against cold air induced bronchoconstriction in asthmatic children
291. Effect of inhaled beclomethasone dipropionate on isocapnic hyperventilation with cold air in asthmatics, measured with forced oscillation technique
292. Airway hyperresponsiveness in asthma: Not just a matter of airway inflammation
293. Safety of inducing sputum in patients with asthma of varying severity
294. Fatal asthma attack during an inhalation challenge with ultrasonically nebulized distilled water
295. Dissimilarity in methacholine and adenosine 5'-monophosphate responsiveness 3 and 24 h after allergen challenge
296. Sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than methacholine in asthma